Francesca Palandri: Prioritizing Anemia Matters in Myelofibrosis
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Clinical Lymphoma, Myeloma and Leukemia, adding:
“Prioritizing anemia matters in myelofibrosis.
Happy to share our latest subgroup analysis from the phase III SIMPLIFY-1 trial, now published in Clinical Lymphoma, Myeloma Leukemia.
We examined momelotinib vs. ruxolitinib in JAK inhibitor–naive myelofibrosis patients with anemia (Hb 10 g/dL).
Key Findings:
- Momelotinib achieved higher dual response rates (spleen reduction and transfusion independence) vs. ruxolitinib: 27% vs. 7%
- In patients with platelets 200 × 10⁹/L, momelotinib showed superior spleen response: 39% vs. 17%
- Transfusion independence correlated with significantly improved overall survival (HR 0.25–0.40)
Prioritizing transfusion independence in anemic MF patients and suggest momelotinib may be preferred in those with lower platelet counts.
Honored to serve as first author of this collaborative work together with an outstanding group of colleagues.
A big thank-you to all my colleagues at IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna.”
Title: Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1
Authors: Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T Oh
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics